Prolia® (denosumab) – FDA drug safety communication
November 22, 2022 - The FDA announced they are investigating the risk of severe hypocalcemia with serious outcomes, including hospitalization and death, in patients with advanced kidney disease on dialysis treated with Prolia (denosumab).
Download PDF
